|
Gene: SLIRP |
Gene summary for SLIRP |
Gene summary. |
Gene information | Species | Human | Gene symbol | SLIRP | Gene ID | 81892 |
Gene name | SRA stem-loop interacting RNA binding protein | |
Gene Alias | C14orf156 | |
Cytomap | 14q24.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9GZT3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
81892 | SLIRP | GSM4909281 | Human | Breast | IDC | 8.33e-06 | 4.21e-01 | 0.21 |
81892 | SLIRP | GSM4909282 | Human | Breast | IDC | 1.34e-05 | 3.84e-01 | -0.0288 |
81892 | SLIRP | GSM4909285 | Human | Breast | IDC | 1.28e-05 | 3.51e-01 | 0.21 |
81892 | SLIRP | GSM4909286 | Human | Breast | IDC | 3.00e-03 | -1.64e-01 | 0.1081 |
81892 | SLIRP | GSM4909290 | Human | Breast | IDC | 5.84e-28 | 7.23e-01 | 0.2096 |
81892 | SLIRP | GSM4909293 | Human | Breast | IDC | 1.01e-06 | 3.36e-01 | 0.1581 |
81892 | SLIRP | GSM4909294 | Human | Breast | IDC | 2.37e-10 | 2.75e-01 | 0.2022 |
81892 | SLIRP | GSM4909296 | Human | Breast | IDC | 2.08e-27 | 5.35e-01 | 0.1524 |
81892 | SLIRP | GSM4909297 | Human | Breast | IDC | 2.95e-19 | 1.85e-01 | 0.1517 |
81892 | SLIRP | GSM4909298 | Human | Breast | IDC | 6.78e-06 | 3.79e-01 | 0.1551 |
81892 | SLIRP | GSM4909301 | Human | Breast | IDC | 1.25e-06 | 3.19e-01 | 0.1577 |
81892 | SLIRP | GSM4909304 | Human | Breast | IDC | 2.27e-12 | 5.02e-01 | 0.1636 |
81892 | SLIRP | GSM4909305 | Human | Breast | IDC | 2.34e-03 | 2.78e-01 | 0.0436 |
81892 | SLIRP | GSM4909307 | Human | Breast | IDC | 3.26e-03 | 3.11e-01 | 0.1569 |
81892 | SLIRP | GSM4909308 | Human | Breast | IDC | 1.72e-05 | 2.39e-01 | 0.158 |
81892 | SLIRP | GSM4909311 | Human | Breast | IDC | 7.53e-51 | 2.20e-01 | 0.1534 |
81892 | SLIRP | GSM4909312 | Human | Breast | IDC | 4.73e-19 | 3.42e-01 | 0.1552 |
81892 | SLIRP | GSM4909316 | Human | Breast | IDC | 3.54e-08 | 4.42e-01 | 0.21 |
81892 | SLIRP | GSM4909317 | Human | Breast | IDC | 3.17e-02 | 2.11e-01 | 0.1355 |
81892 | SLIRP | GSM4909319 | Human | Breast | IDC | 6.62e-49 | -1.01e-01 | 0.1563 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00194394 | Colorectum | FAP | aromatic compound catabolic process | 100/2622 | 467/18723 | 6.75e-06 | 2.08e-04 | 100 |
GO:19023693 | Colorectum | FAP | negative regulation of RNA catabolic process | 25/2622 | 75/18723 | 1.74e-05 | 4.42e-04 | 25 |
GO:19013614 | Colorectum | FAP | organic cyclic compound catabolic process | 101/2622 | 495/18723 | 4.87e-05 | 9.93e-04 | 101 |
GO:00705843 | Colorectum | FAP | mitochondrion morphogenesis | 9/2622 | 21/18723 | 1.22e-03 | 1.14e-02 | 9 |
GO:000640110 | Endometrium | AEH | RNA catabolic process | 63/2100 | 278/18723 | 3.28e-08 | 1.87e-06 | 63 |
GO:003133016 | Endometrium | AEH | negative regulation of cellular catabolic process | 53/2100 | 262/18723 | 1.40e-05 | 2.99e-04 | 53 |
GO:003465510 | Endometrium | AEH | nucleobase-containing compound catabolic process | 74/2100 | 407/18723 | 1.78e-05 | 3.65e-04 | 74 |
GO:004427010 | Endometrium | AEH | cellular nitrogen compound catabolic process | 80/2100 | 451/18723 | 2.09e-05 | 4.13e-04 | 80 |
GO:00467009 | Endometrium | AEH | heterocycle catabolic process | 79/2100 | 445/18723 | 2.27e-05 | 4.35e-04 | 79 |
GO:000989515 | Endometrium | AEH | negative regulation of catabolic process | 60/2100 | 320/18723 | 4.32e-05 | 7.28e-04 | 60 |
GO:00194399 | Endometrium | AEH | aromatic compound catabolic process | 80/2100 | 467/18723 | 7.21e-05 | 1.10e-03 | 80 |
GO:19013619 | Endometrium | AEH | organic cyclic compound catabolic process | 83/2100 | 495/18723 | 1.13e-04 | 1.60e-03 | 83 |
GO:19023699 | Endometrium | AEH | negative regulation of RNA catabolic process | 16/2100 | 75/18723 | 8.13e-03 | 4.49e-02 | 16 |
GO:000640115 | Endometrium | EEC | RNA catabolic process | 65/2168 | 278/18723 | 1.90e-08 | 1.16e-06 | 65 |
GO:003133017 | Endometrium | EEC | negative regulation of cellular catabolic process | 55/2168 | 262/18723 | 7.93e-06 | 1.80e-04 | 55 |
GO:004427013 | Endometrium | EEC | cellular nitrogen compound catabolic process | 83/2168 | 451/18723 | 1.17e-05 | 2.43e-04 | 83 |
GO:004670013 | Endometrium | EEC | heterocycle catabolic process | 82/2168 | 445/18723 | 1.26e-05 | 2.55e-04 | 82 |
GO:003465514 | Endometrium | EEC | nucleobase-containing compound catabolic process | 76/2168 | 407/18723 | 1.61e-05 | 3.12e-04 | 76 |
GO:001943913 | Endometrium | EEC | aromatic compound catabolic process | 83/2168 | 467/18723 | 4.32e-05 | 7.10e-04 | 83 |
GO:000989516 | Endometrium | EEC | negative regulation of catabolic process | 61/2168 | 320/18723 | 5.76e-05 | 8.97e-04 | 61 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLIRP | SNV | Missense_Mutation | novel | c.8C>A | p.Ala3Asp | p.A3D | Q9GZT3 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C8-A26X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
SLIRP | SNV | Missense_Mutation | novel | c.179G>T | p.Arg60Ile | p.R60I | Q9GZT3 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SLIRP | SNV | Missense_Mutation | novel | c.248N>C | p.Ile83Thr | p.I83T | Q9GZT3 | protein_coding | tolerated(0.07) | benign(0.084) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
SLIRP | SNV | Missense_Mutation | novel | c.221N>A | p.Arg74Gln | p.R74Q | Q9GZT3 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AX-A1C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLIRP | SNV | Missense_Mutation | c.20G>A | p.Arg7Lys | p.R7K | Q9GZT3 | protein_coding | tolerated(0.24) | benign(0.005) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
SLIRP | SNV | Missense_Mutation | c.20N>A | p.Arg7Lys | p.R7K | Q9GZT3 | protein_coding | tolerated(0.24) | benign(0.005) | TCGA-DD-AADG-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
SLIRP | SNV | Missense_Mutation | c.80N>T | p.Pro27Leu | p.P27L | Q9GZT3 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-CG-5726-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SLIRP | SNV | Missense_Mutation | novel | c.134N>C | p.Val45Ala | p.V45A | Q9GZT3 | protein_coding | deleterious(0) | possibly_damaging(0.903) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |